Boiron: FY 2017 sales flat

(CercleFinance.com) - Boiron's Q4 2017 sales fell by 1.
1% (-0.4% at constant exchange rates).

Sales of common name drugs fell by 3.2%, although specialty drug sales increased by 1.1%. Sales fell by 13.3% in Russia, although rose by 2.3% in France and 13.2% in the US.

Annual revenues came in at 617,540,000 euros, flat compared to 2016 (+ .5% at current rates and +0.1% at constant rates).
2017 operating income is expected to be lower than in 2016.


Copyright (c) 2018 CercleFinance.com. All rights reserved.